Pricing News: Breaking Pricing News, Comments and Articles. - Page: 5

Neuropathy Diagnosis Obstacles Damaging to Patients' Health

For National Neuropathy Awareness Week (May 13-17), The Neuropathy Association and the Hereditary Neuropathy Foundation Call Attention to the Diagnostic Challenges Hurting Millions of Neuropathy Patients. New York, NY (PRWEB) May 16, 2013 Continued lack of peripheral neuropathy awareness combined with Medicare reimbursement cuts for diagnostic tools are causing major impediments to neuropathy epi...

Novelos Therapeutics Provides Product Pipeline Update

MADISON, Wis., May 16, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today provided an update on its product pipeline, including I-124-CLR1404 (LIGHT) positron emission tomography (PET) imaging agent for solid tumor indications, I-131-CLR1404 (HOT) cancer-targeted molecul...

Ambit Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, May 16, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share.  Ambit has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 shares at the initial public offering price to cover over-allotments, if any.  Ambit's common stock is...

Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook

Companion diagnostics in oncology – Key questions manufacturers should ask to prepare for market access New York, NY (PRWEB) May 16, 2013 Leading UK company, PRMA Consulting launches PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology, a unique handbook that addresses the key issues that biopharmaceutical manufacturers should understand when developing new...

Brooklyn Academy Roots Offers 50% Off Pilates Springboard Classes With Pre-Registration

Fitness studio in Jack London Square offering half-off packages for Pilates classes in Oakland when pre-registering before July 1st. Oakland, CA (PRWEB) May 16, 2013 Boutique self-defense and pilates studio in Oakland, Brooklyn Academy Roots, is offering $7-9 per class for a limited time only when purchased before start date of classes. Classes run 45 minutes and will begin July 1st, Monday throu...

Xeljanz, Nouriast priced and set for Japan launch

The latest reimbursement price listing in Japan will pave the way for the first launch anywhere of two drugs, Kyowa Hakko Kirin's Nouriast (istradefylline) for Parkinson's disease and Zeria's Acofide (acotiamide) for functional dyspepsia......

Zane Benefits Publishes New Information on Exchange Navigators

Park City, Utah (PRWEB) May 16, 2013 Today, Zane Benefits, Inc. published new information on Exchange Navigators . Zane Benefits, which provides comprehensive and flexible alternatives to traditional employer sponsored health benefits, is the lea...

Stem Cell Therapeutics to Begin Trading on the U.S. OTCQX Marketplace

TORONTO, ONTARIO -- (Marketwired) -- 05/16/13 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, today announced that the Company's stock will trade on OTCQX International under the symbol "SCTPF" starting May 20. OTCQX is the premier U.S. Over-The-Counter marketplace, allowing international companies increased access...

VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

MOUNTAIN VIEW, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today the pricing of its offering of $220 million aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 (the "Notes") in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). VIVUS has granted to the initial purchaser...

StoneMor Partners L.P. Announces Pricing of Private $175 Million Debt Offering

LEVITTOWN, Pa., May 16, 2013 (GLOBE NEWSWIRE) -- StoneMor Partners L.P. (NYSE:STON) ("StoneMor") announced today that it and its wholly owned subsidiary, Cornerstone Family Services of West Virginia Subsidiary, Inc. ("CFS West Virginia" and together, the "Issuers"), priced a private offering to eligible purchasers of $175 million aggregate principal amount of Senior Notes due 2021 (the "Notes")....

University General Health System Provides Market Guidance Regarding First Quarter Results

HOUSTON, TX -- (Marketwired) -- 05/16/13 -- University General Health System, Inc. (OTCQB: UGHS), a diversified, integrated multi-specialty health care delivery system, today announced certain preliminary information regarding the quarter ended March 31, 2013. The Company expects to report that first quarter 2013 occupancy at its flagship hospital in Houston exceeded prior-year levels by over 21...

AMI Research Initiates Coverage on Diagnostic Imaging International Corp. With a Speculative Buy Rating of $0.62

LAS VEGAS, NEVADA -- (Marketwired) -- 05/16/13 -- AMI Research, a leading provider of equity research reports and a subsidiary of Hawk Associates Inc., announced today that it has initiated equity research coverage on Diagnostic Imaging International Corp. (OTCQB: DIIG) with a Speculative Buy rating of $0.62 per share. AMI president Peter J. D'Agostino said, "We think DIIG is poised for substan...

Elan Announces Publication of Response Document

Elan Corporation, plc (NYSE : ELN) (Elan) today announces publication of a response document in respect of the Echo Pharma Acquisition Limited (Royalty Pharma) offer made on May 2, 2013. The response document is published in accordance with Rules 25 and 30.3 of the Irish Takeover Rules and the United States tender offer rules. As previously advise...

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating m...

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatmen...

Posit Science Supplies Brain Fitness Exercises for New AARP Service

SAN FRANCISCO, May 15, 2013 /PRNewswire/ -- Posit Science, the brain fitness company, announced it is supplying online exercises through its BrainHQ platform to AARP for a new AARP service called "AARP Brain Fitness powered by BrainHQ."  The service is now live at brain.aarp.org. (Photo: http://photos.prnewswire.com/prnh/20130515/NE15027-a ) (Photo: http://photos.prnewswire.com/...

Novartis loses bid to stop German gliptin review

A German court on Wednesday dismissed a suit from Novartis AG (NYSE:NVS; SIX:NOVN) seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. Preliminary assessments on the...

Earnings – a snapshot of one point in time

The 6 W’s: Who, what, where, when, why and what of it RegMed sector companies’ Q1 earnings continue to come forth.  Yesterday I reminded everyone that for a day or two we then see lower pricing, but as earnings work way through the traders marke...

Mathew Whelan Joins Remedi SeniorCare® as Vice President and Corporate Controller

BALTIMORE, May 15, 2013 /PRNewswire/ -- Remedi SeniorCare® has named Mathew Whelan as Vice President and Corporate Controller. With over 20 years of experience building and leading accounting teams, Matt will serve as a key member of the corporate financial team and will be responsible for managing and overseeing all facets of Remedi's accounting operations. (Logo:  http://photos....

Vasomedical Announces Financial Results for the First Quarter of 2013

WESTBURY, N.Y., May 15, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO) today reported its operating results for the three months ended March 31, 2013. "We are pleased to report that for the first quarter of 2013, we recorded total revenue of $7.3 million, an increase of 21% compared to the same period of 2012," commented Dr. Jun Ma, President and Chief Executive Officer of...

Exclusive: Roche exploring sale of diabetes device unit

By Jessica Toonkel NEW YORK (Reuters) - Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition an...

Demand for Dental Care Drives Growth in the Dental Orthodontic Supplies Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Dental Orthodontic Supplies markets. Global market for Dental Orthodontic Supplies is projected to reach US$1.1 billion by 2018, driven by increasing volumes of orthodontic procedures due to rising awareness about dental care. San Jose, CA (PRWEB) May 15, 2013 Follow us on LinkedIn - Orthodontic supplies, although a small category in t...

Launching new drugs in the Outcome Era; report

The pharmaceutical industry is facing the Outcome Era. Launching a novel drug today obliges companies to convince on its value. They have to prove the best possible health outcomes and additional benefit to achieve adequate price and reimbursement, a...

Emerging Biomarker Companies Redux: Positioned For Growth

By Rod Raynovich: Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 UpdateThe synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted therapeutics.The development of unique biomarkers has been considered the "Holy Grail" of innovation in diagnostic...

Running a Lean, Mean AP Lab Machine with NovoPath: Executive War College Attendees Focus on Economic Challenges Facing the Anatomic Pathology Community

The new realities of ongoing anatomic pathology (AP) laboratory reimbursement cuts figured prominently in the topics discussed at the recent Executive War College in April. One of the ways labs across the country are addressing financial pressure is through Lean Process Improvement, which is included in NovoPath's AP lab management system. Princeton, NJ (PRWEB) May 15, 2013 Deep, wide and al...